A “worst case scenario” where Beovu is withdrawn from the market cuts earnings per share by 4% and would add to Novartis’ woes following the phase 3 trial failure of fevipiprant for asthma.

Beovu was intended to maintain Novartis' anti-VEGF franchise once Lucentis starts to fade, and had been predicted to become a $2.5 billion product before the safety issue emerged. Image Phil Taylor ...

Who Are the Leading Players in the Beovu Brolucizumab Market? Novartis AG is a key player at the forefront of the Beovu brolucizumab market, driving innovation and business expansion. How Is ...